Sugi Predict

Sugi Predict / Compounds / SCHEMBL2480988

SCHEMBL2480988

SCHEMBL2480988

CC(C)(C)OC(=O)N1CCNC[C@H]1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.47
▸ PARP1 P09874 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NPC1 O15118 1/20 0.36
▸ MC4R P32245 1/20 0.36
▸ MC5R P33032 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480835 1.00 HSD17B10 (0.47) HSD17B10PARP1SMN1; SMN2NPC1MC4R
SCHEMBL1685922 1.00 HSD17B10 (0.47) HSD17B10PARP1SMN1; SMN2NPC1MC4R
Piperazine SCHEMBL28831394 0.97 HSD17B10 (0.45) HSD17B10PARP1SMN1; SMN2NPC1MC4R
Piperazine SCHEMBL28831395 0.97 HSD17B10 (0.45) HSD17B10PARP1SMN1; SMN2NPC1MC4R
SCHEMBL7995550 0.88 PARP1 (0.44) HSD17B10PARP1SMN1; SMN2NPC1MC4R
SCHEMBL2584375 0.88 PARP1 (0.44) HSD17B10PARP1SMN1; SMN2NPC1MC4R
SCHEMBL18673224 0.88 PARP1 (0.44) HSD17B10PARP1SMN1; SMN2NPC1MC4R
SCHEMBL28704904 0.88 PARP1 (0.44) HSD17B10PARP1SMN1; SMN2NPC1MC4R
SCHEMBL15402543 0.86 PARP1 (0.43) HSD17B10PARP1SMN1; SMN2NPC1MC4R
SCHEMBL17560433 0.86 PARP1 (0.43) HSD17B10PARP1SMN1; SMN2NPC1MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368625-A1 PIPERAZINES Grünenthal GmbH (DE) 2025-12-04 — — US disclosed
US-12428427-B2 Methods and compositions for targeting PD-L1 ALIGOS THERAPEUTICS, INC. (US) 2025-09-30 — — US disclosed
WO-2025049804-A2 AGENTS FOR THE TREATMENT OF NON-REPLICATING BACTERIA ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2025-03-06 — — WO disclosed
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 — — EP disclosed
US-20230192713-A1 METHODS AND COMPOSITIONS FOR TARGETING PD-L1 ALIGOS THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-11679108-B2 Aromatic heterocyclic compound, and pharmaceutical composition and use thereof GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) 2023-06-20 — — US disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 — — WO disclosed
WO-2022263820-A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY Z Factor Limited (GB) 2022-12-22 — — WO disclosed
WO-2022263820-A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY Z Factor Limited (GB) 2022-12-22 — — WO disclosed
EP-3805234-A1 AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Guangzhou Henovcom Bioscience Co., Ltd. (CN) 2021-04-14 — — EP disclosed
EP-1664029-B1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2009-12-02 — — EP disclosed
WO-2009003911-A1 THIOPHENE-IMIDAZOPYRIDINES 4SC AG (DE) 2009-01-08 — — WO disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 — — EP disclosed
US-20070015743-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2007-01-18 — — US disclosed
CN-1882572-A Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2006-12-20 — — CN disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 — — US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 — — EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 — — WO disclosed
WO-1995000498-A1 N,N-DIACYLPIPERAZINES MERCK & CO., INC. (US) 1995-01-05 — — WO disclosed
US-5348955-A Angiotensis II antagonists MERCK & CO., INC. (US) 1994-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015743-A1 Quinazoline derivatives as antitumor agents ERBB2, ABL1, EGFR HSD17B10 4096/4885PARP1 967/4885SMN1; SMN2 4263/4885
US-20230192713-A1 METHODS AND COMPOSITIONS FOR TARGETING PD-L1 CD274, PDCD1LG2, PDCD1 HSD17B10 712/4885PARP1 2933/4885SMN1; SMN2 3106/4885
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 HSD17B10 3149/4885PARP1 296/4885SMN1; SMN2 4323/4885
US-12428427-B2 Methods and compositions for targeting PD-L1 CD274, PDCD1LG2, PDCD1 HSD17B10 712/4885PARP1 2933/4885SMN1; SMN2 3106/4885
US-11679108-B2 Aromatic heterocyclic compound, and pharmaceutical composition and use thereof ENPP2, ADRM1, TPX2 HSD17B10 2116/4885PARP1 1824/4885SMN1; SMN2 792/4885
US-20250368625-A1 PIPERAZINES SSTR4, SSTR5, SSTR2 HSD17B10 3303/4885PARP1 4279/4885SMN1; SMN2 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.